Mark Rayder
🏛️ Revolving DoorFormer Government Position:
LA, Rep. Tom Latham; LA, Rep. Rodney Frelinghuysen; District Rep., Rep. Dean Gallo.
🤖
AI Overview
Mark Rayder has appeared in 1,366 federal lobbying filings at Alston & Bird LLP, representing 50 clients. As a former government official, they bring insider expertise to their lobbying work — part of Washington's "revolving door." Active across 21 policy areas.
1,366
Total Filings
1
Firms
50
Clients
21
Issue Areas
Issue Areas
Filing History
| Year | Filings | Clients |
|---|---|---|
| 2018 | 166 | 21 |
| 2019 | 138 | 18 |
| 2020 | 158 | 24 |
| 2021 | 144 | 23 |
| 2022 | 160 | 22 |
| 2023 | 241 | 29 |
| 2024 | 167 | 27 |
| 2025 | 192 | 28 |
Firms
Alston & Bird LLP1366 filings
Top Clients
Travere Therapeutics150 filings
The Metrohealth System88 filings
Novo Nordisk INC.84 filings
American College of Gastroenterology83 filings
Hologic, INC.55 filings
Tivity Health, INC.50 filings
Academy of General Dentistry48 filings
Eyecare Partners LLC46 filings
American Ambulance Association36 filings
The Nrp Group LLC33 filings
St. Jude Children's Research Hospital26 filings
Alabama Hospital Association26 filings
Novartis Corporation24 filings
American Clinical Laboratory Association24 filings
Regents of the University of Michigan23 filings
Iowa Donor Network23 filings
Biomerieux, INC.23 filings
Related Analysis
Related Investigations
The Revolving Door Exposed
How former government officials become the most powerful lobbyists.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.